Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanobiotix ( (NBTX) ) has issued an update.
On April 20, 2026, Nanobiotix reported new preclinical data for its Nanoprimer platform, presented at the American Association for Cancer Research annual meeting, showing that pretreatment with Nanoprimer in mice improved the performance of lipid nanoparticle-delivered recombinant DNA immunotherapy. In these studies, Nanoprimer was administered intravenously before LNP-DNA constructs designed for anti-tumor immunotherapy, aiming to address the common problem of rapid liver clearance that limits systemic bioavailability and increases toxicity.
The data indicated reduced liver uptake and improved hepatic tolerability of LNP-DNA, higher circulating levels of the therapeutic payload, and attenuation of cGAS-STING–related inflammatory responses when compared with LNP-DNA given alone. Nanobiotix, which is pursuing a dual strategy of external collaborations and an internal pipeline, said the results—generated with partner Earli—support broader exploration of Nanoprimer as a companion platform to optimize advanced extrahepatic LNP systems, signaling potential operational and partnering opportunities as drug developers seek safer and more effective delivery for complex modalities.
The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The score is held back mainly by weak financial fundamentals—ongoing losses, consistent cash burn, and balance-sheet pressure from negative equity and higher debt. Offsetting this, technicals are relatively strong with an upward trend and positive MACD, while the latest earnings update was constructive on liquidity/runway and clinical progress but tempered by one-off revenue effects and dependency on J&J-controlled timelines.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market, developing physics-based nanotherapeutic platforms for oncology, bioavailability and biodistribution, and central nervous system disorders. Founded in 2003 and backed by more than 30 umbrella patents, the company focuses on disruptive technologies such as its Nanoprimer platform to enhance the performance of advanced therapies including RNA, gene therapies, biologics, and other cancer treatments by improving systemic delivery and reducing liver-related side effects.
Through subsidiaries in Cambridge, Mass., and other locations, Nanobiotix is advancing both proprietary assets and strategic collaborations built around Nanoprimer as a companion platform. The technology is designed to transiently modulate liver uptake so that complex medicines circulate longer, achieve greater accumulation at target tissues, and potentially unlock therapeutic approaches that previously failed due to hepatic clearance and toxicity constraints.
Average Trading Volume: 49,419
Technical Sentiment Signal: Buy
Current Market Cap: $1.61B
See more insights into NBTX stock on TipRanks’ Stock Analysis page.